Leaky gut in treated HIV: scientists probe why immune repair fails

NCT ID NCT02906137

Completed Knowledge-focused Sponsor: ANRS, Emerging Infectious Diseases Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study investigates why the gut immune barrier remains damaged in people with HIV even after successful antiretroviral therapy. Researchers collected blood and intestinal biopsies from 80 participants to measure immune cells and inflammation. The goal is to understand why the gut doesn't fully recover, which could help reduce long-term health problems.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could point toward new ways to help the gut immune system recover in people living with HIV, potentially reducing long-term inflammation.
What could go wrong: This is an observational study, not a treatment trial. It aims to understand the problem, not test a solution. Results may not lead directly to new therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV-1-INFECTION

Contacts and locations

Locations

Hôpital Purpan - Service de Médecine Interne

Toulouse, 31059, France
Hôpital Purpan - Service des maladies Infectieuses

Toulouse, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.